• Medicine
  • Published 2001

Telithromycin. Author's Reply

@inproceedings{Balfour2001TelithromycinAR,
  title={Telithromycin. Author's Reply},
  author={Julia A. Balfour and David P. Figgitt and Arthur L. Barry and S. Ragnar Norrby},
  year={2001}
}
Telithromycin is the first member of a new family of the macrolide-lincosamide-streptogramin-B (MLS B ) class of antimicrobials, the ketolides. It has a good spectrum of activity against respiratory pathogens, including penicillin-and erythromycin-resistant pneumococci, as well as intracellular and atypical bacteria. Furthermore, it has a low potential to select for resistance or induce cross-resistance among other MLS B antimicrobials. At the recommended dosage of 800mg orally once daily… CONTINUE READING

Topics from this paper.